Deoxycytidine kinase explained

Deoxycytidine kinase (dCK) is an enzyme which is encoded by the DCK gene in humans.^[1] dCK predominantly phosphorylates deoxycytidine (dC) and converts dC into deoxycytidine monophosphate. dCK catalyzes one of the initial steps in the nucleoside salvage pathway^[2] and has the potential to phosphorylate other preformed nucleosides, specifically deoxyadenosine (dA) and deoxyguanosine (dG), and convert them into their monophosphate forms.^[3] There has been recent biomedical research interest in investigating dCK's potential as a therapeutic target for different types of cancer.

Structure

dCK is a homodimer where each monomer subunit consists of multiple alpha helices surrounding a beta sheet core. Each subunit includes a nucleotide donor binding site, nucleoside acceptor binding site, nucleotide base sensing loop (240-254 residues), insert region (12-15 residues) that connects helices 2 and 3.^[4] dCK has several different protein conformations but its conformation depends on the nucleoside or nucleotide it binds to. dCK can bind to ADP, ATP, UDP or UTP (phosphoryl group donors) but UDP/UTP binding changes the enzyme's conformation by rearranging the nucleotide base sensing loop as compared to the dCK's conformation when bound to ATP. This change in conformation when a specific phosphoryl donor is bound in the nucleotide binding site determines which nucleoside can bind in the nucleoside binding site. For example, it has been observed that when dCK binds to ADP, dCK takes on a "closed" conformation or more compact nucleoside binding site where glutamic acid 53 (Glu53) is brought into closer proximity to directly interact with the nucleoside's 5' hydroxyl group.

One hypothesis for the functionality of the "open" conformation is that the "open" conformation may assist in the initial nucleoside binding and the release of the monophosphate product

Function

Deoxycytidine kinase (dCK) phosphorylates several deoxyribonucleosides and their nucleoside analogues (a nucleoside with a sugar and a different nucleic acid base substitute or analogue that has unique properties when modified) using phosphate groups from ATP and UTP. More specifically, dCK adds the first phosphoryl group to preformed nucleosides and is usually the rate-limiting enzyme of the overall process of converting nucleosides to their deoxynucleoside triphosphate form, or nucleotide form, in the nucleoside salvage pathway. Below is a simplified pathway that displays dCK's role in synthesizing nucleotides using the nucleoside salvage pathway.

Glu53 performs base catalysis to deprotonate the hydroxyl group, which allows the now nucleophilic oxygen from the nucleoside 5' hydroxyl group to attack the end of the phosphate chain (gamma phosphate) on the phosphoryl donor (e.g. ATP or UTP). This has deemed the "closed" conformation as the catalytically active conformation since it catalyzes the phosphoryl transfer between phosphoryl donors and receiving nucleosides. Similarly, "open" conformation is generally referred to as the catalytically inactive form since Glu53 is not in close proximity to nucleoside 5' hydroxyl group and will not catalyze the phosphoryl transfer.

Regulation

One method of to regulate both catalytic activity and substrate specificity is a post-translational modification on Serine 74, a residue in the insert region on each of the individual dCK subunits. Although serine 74 is far from dCK's active site, phosphorylation of serine 74 (Ser74) on dCK causes a change in enzyme conformation and influences enzyme kinetics. More specifically, phosphorylation of Ser74 favors dCK to adopt its open (inactive) conformation and allow dCK to become more competent in binding and releasing nucleosides but restricts dCK from transferring phosphoryl groups. dCK's closed (active) conformation allows dCK to transfer phosphoryl groups, but not bind or release nucleosides. The "open" and "closed" states refer to the nucleoside binding site on dCK.^[5]

Nucleotide biosynthesis

dCK is a key enzyme in the nucleoside salvage pathway (NSP). More specifically, this pathway recycles preformed nucleosides from degrading DNA molecules to synthesize dNTPs for the cell. The nucleoside salvage pathway can act as an alternative path to produce nucleotides (dNTP's) in case of de novo pathway downregulation. That is, the salvage pathway (and thus dCK) is upregulated when the de novo pathway is downregulated or inhibited in order to compensate for the loss in nucleotide production. Both the de novo pathway (DNP) and the nucleoside salvage pathway (NSP) are anabolic pathways that produce deoxyribonucleotide triphosphates (dNTP's) or nucleotides, the monomers that make up DNA.

Therapeutic implications

Deficiency of dCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these agents to cytotoxic nucleoside triphosphate derivatives. dCK is clinically important because of its relationship to drug resistance and sensitivity. Manipulating dCK's enzymatic activity has been shown to have a strong correlation in sensitizing cells to the effects of other drugs (e.g. RNR inhibitors, gemcitabine) or treatments (e.g. ionizing radiation)^[6] and so more combination therapies are currently been studied to reduce biological resistance mechanisms and drug tolerance in patients.^[7]

For example, gemcitabine is a FDA-approved pyrimidine nucleoside analogue and a dCK activity based prodrug that has been used to treat pancreatic, breast, bladder and non-small cell lung cancer. Mechanistically, dCK, which uptakes preformed nucleosides, adds the first phosphoryl group on dFdC (gemcitabine's original form as a deoxycytidine analog) to convert it into dFdCMP, its monophosphate form. Cytidylate kinase or UMP-CMP kinase then adds the second phosphoryl group to form dFdCDP (gemcitabine diphosphate form), which can inhibit ribonucleotide reductase. Nucleoside-diphosphate kinase or nucleoside kinase A adds the third phosphoryl group to form dFdCTP (gemcitabine triphosphate form) which is gemcitabine's active form which inhibits both deoxycytidylate deaminase and DNA polymerase.^[8] Although gemcitabine has widely used to treat solid tumors for over a decade, patients taking gemcitabine alone (monotherapy) have been observed to develop chemoresistance to the drug.

Notes and References

Web site: Entrez Gene: DCK deoxycytidine kinase.
Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG . Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication . The Journal of Experimental Medicine . 211 . 3 . 473–86 . March 2014 . 24567448 . 3949575 . 10.1084/jem.20131738 .
Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A . Structure of human dCK suggests strategies to improve anticancer and antiviral therapy . en . Nature Structural Biology . 10 . 7 . 513–9 . July 2003 . 12808445 . 10.1038/nsb942 . 11858/00-001M-0000-0012-F0B9-8 . 6212685 . free .
Sabini E, Hazra S, Konrad M, Lavie A . Elucidation of Different Binding Modes of Purine Nucleosides to Human Deoxycytidine Kinase . Journal of Medicinal Chemistry . 51 . 14 . 4219–25 . July 2008 . 18570408 . 2636677 . 10.1021/jm800134t .
Hazra S, Szewczak A, Ort S, Konrad M, Lavie A . Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release . Biochemistry . 50 . 14 . 2870–80 . April 2011 . 21351740 . 3071448 . 10.1021/bi2001032 .
Grégoire V, Rosier JF, De Bast M, Bruniaux M, De Coster B, Octave-Prignot M, Scalliet P . Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro . Radiotherapy and Oncology . 63 . 3 . 329–38 . June 2002 . 12142097 . 10.1016/s0167-8140(02)00106-8 .
Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA, Vogelstein B, Nowak MA . Evolutionary dynamics of cancer in response to targeted combination therapy . eLife . 2 . e00747 . June 2013 . 23805382 . 3691570 . 10.7554/eLife.00747 . free .
de Sousa Cavalcante L, Monteiro G . Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer . European Journal of Pharmacology . 741 . 8–16 . October 2014 . 25084222 . 10.1016/j.ejphar.2014.07.041 .